总的来说，中源协和VUM03注射液的临床试验获批，标志着干细胞治疗在克罗恩病及其并发症中的应用迈出了重要一步。这一进展不仅为患者带来了新的希望，也为未来治疗慢性炎症性疾病提供了新的思路。我们期待这一创新疗法能够早日惠及更多患者，为他们的健康保驾护航。

北京商报讯（记者 丁宁）3月31日晚间，中源协和（600645）发布公告称，公司全资子公司武汉光谷中源药业有限公司于3月28日收到国家药品监督管理局核准签发的关于VUM03注射液用于治疗非活动性/轻度活动性克罗恩病复杂性肛瘘的《药物临床试验批准通知书》。 公告显示，VUM03注射液（人脐带源间充质干/基质细胞注射液）是中源协和自主研发的冷冻保存型细胞制剂，是由经筛选的健康新生儿脐带组织通过体外分离 ...

Our MSc programmes are designed to question conventional thinking by skilfully combining different disciplines to foster innovation and generate unexpected insights. Taught and curated by industry ...

Researchers at academic institutions nationwide say that U.S. science is being dismantled. Government Science Data: Vast ...

USA: A recent study has highlighted the potential benefits of tirzepatide for overweight and obese adults with type 1 ...

Loneliness has become a global health crisis, linked to depression, dementia, and early death. With over a billion people ...

For the second year in a row, UC Santa Cruz undergraduate computer engineering student Astra Tsai was the fastest student to solve the National Security Administration’s (NSA) codebreaker challenge.

Finishing my morning work, The Gracious Mistress of the Parsonage appeared at my office and asked, “Do you know what day it is?” ...

Hypertension, commonly known as high blood pressure, affects an estimated one in three adults globally. This serious health ...

A new high-level scientific Advisory Board has been established to accompany and support the research, clinical, and ...